Publications by authors named "David Clifford"

Claim this Profile
A
A Multi-Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions.
Giovanna S Manzano, Denis Balaban, Yihan Zhang, Brian Healy, Bart K Chwalisz, David B Clifford

Ann Clin Transl Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards pharmacological prevention of Alzheimer disease.
Jorge J Llibre-Guerra, Eric M McDade, Suzanne E Schindler, David B Clifford, Charlene Supnet

Nat Rev Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers.
Nelly Joseph-Mathurin, Charles D Chen, Diana A Hobbs, Meng Jiang, Shaney Flores, Clifford R Jack, David B Clifford

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
Aleksandar Videnovic, Christopher S Coffey, Elizabeth B Klerman, Merit Cudkowicz, Hyun Joo Cho, David Clifford

Mov Disord· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GATA2 mutation is associated with immune dysfunction and increased Mycobacterium haemophilum susceptibility in immunocompromised individuals.
Ananya Gupta, Shail B Mehta, , Bruce A Rosa, John Martin, David B Clifford

JCI Insight· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.
Eric M McDade, Nicolas R Barthélemy, Guoqiao Wang, Yan Li, Yuchen Cao, David Clifford

Alzheimers Dement· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.
Yan Li, Jorge J Llibre-Guerra, Charlene Supnet, Alireza Atri, Eric M McDade, David B Clifford

Lancet Neurol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.
Austin McCullough, Charles D Chen, Brian A Gordon, Nelly Joseph-Mathurin, Clifford R Jack, David B Clifford

Alzheimers Dement· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial.
Ka-Ho Wong, Gregory Scott Day, James C Torner, Merit Cudkowicz, Christopher S Coffey, David B Clifford

Neurol Open Access· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.
Giovanna Sophia Manzano, James Eaton, Michael Levy, Justin R Abbatemarco, Allen J Aksamit, David B Clifford

Neurol Clin Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Clifford R Jack

Lancet Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Clifford R Jack

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopsychosocial phenotypes in people with HIV in the CHARTER cohort.
Bin Tang, Ronald J Ellis, Florin Vaida, Anya Umlauf, Donald R Franklin, David B Clifford

Brain Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Olivia Wagemann, Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner, David B Clifford

JAMA Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
Guoqiao Wang, Yan Li, Chengjie Xiong, Tammie L S Benzinger, Brian A Gordon, David B Clifford

Alzheimers Dement· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterium haemophilum Related Myelitis in Geographically Linked Cases.
Rohini D Samudralwar, Thomas C Bailey, Ananth K Vellimana, Neill M Wright, David B Clifford

Ann Neurol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender inequalities in unpaid public work: Retention, stratification and segmentation in the volunteer leadership of charities in England and Wales.
David Clifford

Br J Sociol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial inequalities in charitable fundraising and income generation for NHS acute trusts in England.
John Mohan, David Clifford

Public Money Manag· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Plasma Protein Carbonyl Concentration Is Associated with More Abnormal White Matter in People with HIV.
Patricia K Riggs, Albert M Anderson, Bin Tang, Leah H Rubin, Susan Morgello, David B Clifford

Viruses· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?
Bruce J Brew, David B Clifford

AIDS· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing Neuroinflammation Relates to Increasing Neurodegeneration in People with HIV.
Azin Tavasoli, Benjamin B Gelman, Christina M Marra, David B Clifford, Jennifer E Iudicello

Viruses· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal head-to-head comparison of C-PiB and F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
Charles D Chen, Austin McCullough, Brian Gordon, Nelly Joseph-Mathurin, Shaney Flores, Clifford Jack, David B Clifford

Eur J Nucl Med Mol Imaging· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The place of charity in a public health service: Inequality and persistence in charitable support for NHS trusts in england.
James Bowles, David Clifford, John Mohan

Soc Sci Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study.
Robert K Heaton, Ronald J Ellis, Bin Tang, Christina M Marra, Leah H Rubin, David B Clifford

Brain· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.
Umesh G Lalloo, Lauren Komarow, Judith A Aberg, David B Clifford, Evelyn Hogg

PLoS One· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis